Strand Daniel S, Cosgrove Natalie D, Patrie James T, Cox Dawn G, Bauer Todd W, Adams Reid B, Mann James A, Sauer Bryan G, Shami Vanessa M, Wang Andrew Y
Division of Gastroenterology and Hepatology, University of Virginia Health System, Charlottesville, Virginia, USA.
Division of Biostatistics and Epidemiology, University of Virginia Health System, Charlottesville, Virginia, USA.
Gastrointest Endosc. 2014 Nov;80(5):794-804. doi: 10.1016/j.gie.2014.02.1030. Epub 2014 May 15.
Cholangiocarcinoma (CCA) is a malignancy with a poor 5-year survival rate (5%-10%). ERCP-directed radiofrequency ablation (RFA) or photodynamic therapy (PDT) can be performed as palliative therapy for unresectable CCA. ERCP with PDT is associated with improved survival compared with stent placement alone. However, ERCP-directed RFA has not been directly compared with PDT in patients with CCA.
To compare overall survival in patients with unresectable CCA who underwent palliative ERCP-directed RFA versus PDT.
Retrospective cohort study.
Tertiary-care academic medical center.
Forty-eight patients with unresectable CCA who underwent ERCP-directed ablative therapy for palliation of unresectable CCA.
ERCP-directed RFA or PDT.
Overall survival by Kaplan-Meier analysis after initial treatment with either RFA or PDT.
Patients who underwent RFA (n = 16) demonstrated an overall survival similar to that of those who underwent PDT (n = 32), with a median survival of 9.6 versus 7.5 months, respectively (P = .799). Patient age (P = .45), sex (P = .52), and lead time (P = .59) from presentation to initial RFA or PDT had no significant association with survival. The presence of distant metastasis was inversely associated with survival (hazard ratio 3.55; 95% confidence interval, 1.29-9.77; P = .014). Patients who underwent RFA (compared with PDT) had a lower mean number of plastic stents placed per month (0.45 vs 1.10, P = .001) but also had more episodes of stent occlusion (0.06 vs 0.02, P = .008) and cholangitis (0.13 vs 0.05, P = .008) per month.
Retrospective, single-center design.
Survival after ERCP-directed RFA and PDT was not statistically different in patients with unresectable CCA. A randomized, controlled trial is warranted to validate these preliminary results.
胆管癌(CCA)是一种5年生存率较低(5%-10%)的恶性肿瘤。内镜逆行胰胆管造影(ERCP)引导下的射频消融(RFA)或光动力疗法(PDT)可作为不可切除CCA的姑息治疗方法。与单纯放置支架相比,ERCP联合PDT可提高患者生存率。然而,在CCA患者中,尚未对ERCP引导下的RFA与PDT进行直接比较。
比较接受姑息性ERCP引导下RFA与PDT治疗的不可切除CCA患者的总生存期。
回顾性队列研究。
三级医疗学术医学中心。
48例因不可切除CCA行ERCP引导下消融治疗以缓解症状的不可切除CCA患者。
ERCP引导下的RFA或PDT。
首次接受RFA或PDT治疗后,采用Kaplan-Meier分析评估总生存期。
接受RFA治疗的患者(n = 16)与接受PDT治疗的患者(n = 32)总生存期相似,中位生存期分别为9.6个月和7.5个月(P = 0.799)。患者年龄(P = 0.45)、性别(P = 0.52)以及从出现症状到首次接受RFA或PDT的间隔时间(P = 0.59)与生存期均无显著相关性。远处转移的存在与生存期呈负相关(风险比3.55;95%置信区间,1.29-9.77;P = 0.014)。接受RFA治疗的患者(与接受PDT治疗的患者相比)每月放置的塑料支架平均数量较少(0.45比1.10,P = 0.001),但每月支架堵塞(0.06比0.02,P = 0.008)和胆管炎(0.13比0.05,P = 0.008)的发作次数更多。
回顾性单中心设计。
在不可切除CCA患者中,ERCP引导下RFA和PDT后的生存期无统计学差异。有必要进行一项随机对照试验来验证这些初步结果。